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PERSPECTIVE

Stemming the Brain Drain

provide solutions to all the complex problems of health worker
migration, it offers needed guidance on possible policy and legislative approaches. There is
growing evidence that its legal
framework can work as a platform for cooperation to strengthen
health workforce systems. Sixtynine countries have thus far designated a national authority responsible for the exchange of
information on health worker migration and Code implementation.
However, greater efforts are need-

ed to ensure effective implementation. It is time for states to muster the political will and resources
to act to strengthen health workforce systems everywhere.
Disclosure forms provided by the authors are available with the full text of this
article at NEJM.org.
From the O’Neill Institute for National and
Global Health Law, Georgetown University
Law Center (A.L.T.); and the Office of the
Secretary, Office of Global Affairs, U.S. Department of Health and Human Services
(N.D.) — both in Washington, DC; the African Group of Health Diplomats, World
Health Organization, Geneva (L.H.); and

the Norwegian Directorate of Health, Oslo
(B.-I.L.).
1. Frenk J, Chen L, Bhutta ZA, et al. Health
professionals for a new century: transforming education to strengthen health systems
in an interdependent world. Lancet 2010;376:
1923-58.
2. Medical Education Partnership Initiative
(MEPI). Bethesda, MD: Fogarty International Center, National Institutes of Health,
June 2010 (http://www.fic.nih.gov/Programs/
Pages/medical-education-africa.aspx).
3. HHS partners with PEPFAR to transform
African medical education with $130M investment. Bethesda, MD: National Institutes of
Health, October 2010 (http://www.fic.nih
.gov/Programs/Pages/medical-educationafrica.aspx).
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Smoking and the First Amendment
Kevin Outterson, J.D.

O

n June 22, 2009, President
Barack Obama signed the
Family Smoking Prevention and
Tobacco Control Act into law.1
For the first time, Congress had
given the Food and Drug Administration (FDA) authority to directly regulate tobacco products,
with the aim of improving public health. And indeed, effective
tobacco control would
A slide show
is available
be a remarkable public
at NEJM.org
health achievement —
and might be possible if the law
is allowed to stand. But on November 7, 2011, a federal judge in
Washington, D.C., issued a preliminary injunction blocking some
of its key provisions as unconstitutional restrictions on commercial speech, and the battle seems
likely to end up in the Supreme
Court.
The Tobacco Control Act made
three changes to cigarette warnings. First, existing warnings on
cigarette packages (which have
been required since 1966) must
be replaced with nine new specified verbal warnings (see box),
one of which must appear on every

package. Second, nine new graphic images must be paired with
the textual warnings on a rotating basis; the FDA selected images
that it expects to have the greatest anti-smoking effect (see images
and slide show). Finally, companies
must move the warnings from the
side of the package and devote at
least the top 50% of both the
front and back panels to the government-mandated messages.
The case decided in November, R.J. Reynolds Tobacco Company v.
FDA,2 challenged the second two
of these three changes, as implemented through an FDA rule
published on June 22, 2011.3 The
judge, Richard Leon, refused to
apply the well-known Central Hudson test for commercial speech,
under which the government must
establish that the rule “directly
advances” its “substantial” interest and is “not more extensive
than is necessary.” Instead, Leon
applied the more demanding
“strict scrutiny” test, whereby the
government’s interest must be
“compelling” and the regulation
“narrowly tailored” to that com-
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pelling purpose. Finding that the
regulation failed this test, the
court enjoined the FDA from enforcing the regulations regarding
graphic images and mandatory
space allocations. The Department of Justice immediately appealed this ruling.
Last year, the FDA fared better
in a case decided in Kentucky,
Commonwealth Brands v. United States,4
in which the court upheld these
new warnings under Central Hudson. Why did these decisions diverge?
First, the selection of the standard of review is key. Under Central Hudson, a court considering
the constitutionality of regulations
examines whether they achieve the
intended purpose, and it explores
the roads not taken — options
available to the government that
could achieve success without
violating the First Amendment.
Under the strict-scrutiny standard,
the inquiry is much more exacting, and few regulations survive it.
In Reynolds Tobacco, the court imposed strict scrutiny because the
graphic images were not “purely
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FDA-Mandated Warnings for Cigarette Packages.
WARNING: Cigarettes are addictive.
WARNING: Tobacco smoke can harm your children.
WARNING: Cigarettes cause fatal lung disease.
WARNING: Cigarettes cause cancer.
WARNING: Cigarettes cause strokes and heart
disease.
WARNING: Smoking during pregnancy can harm
your baby.
WARNING: Smoking can kill you.
WARNING: Tobacco smoke causes fatal lung disease in nonsmokers.
WARNING: Quitting smoking now greatly reduces
serious risks to your health.

factual and noncontroversial” but
were instead very striking images
designed to maximize “salience”
and emotional impact. By contrast, the court in Commonwealth
Brands found the graphic images
to be well suited to the purposes
of the Tobacco Control Act.
Which brings us to the second key question: What is the
purpose of the Tobacco Control
Act? Public health experts might
believe that the substantial state
interest behind the law was reducing the health effects of tobacco
use. But when a law restricts commercial speech, courts seek precise justifications for the regulations at issue. The question
therefore narrows to the purpose
of the graphic-image and spaceallocation rules. In Commonwealth
Brands, the government successfully argued that its substantial
interest was warning people
about the dangers of smoking.
The tobacco companies insisted
the goal was correcting consumer
ignorance about the health risks
of smoking. Although these goals
seem similar, they lead to remarkably different legal results.
The tobacco companies argued
that “numerous national surveys
demonstrate that over the last
2352

half century, the awareness of
smoking-related risks is widespread.” In fact, in their view,
“‘surveys demonstrate that Americans perceive a significantly
higher lost life expectancy due to
smoking’ than is warranted based
on the Surgeon General’s reports,
and ‘young people overestimate
the dangers of smoking to an
even greater degree’ than adults.”4
In short, the companies say,
Americans already know too much
about the dangers of tobacco use
and don’t need new graphic
warnings.
The court in Commonwealth
Brands did not disagree with this
empirical research but found it
irrelevant. In that case, Judge Joseph McKinley concluded that the
government’s substantial interest
“is to ensure that the health risk
message is actually seen by consumers in the first instance.” If
that is the goal, then large graphic warnings on all cigarette packages are appropriate. The court
found support in a 2007 report
from the Institute of Medicine,
which found existing warnings
to be “unnoticed and stale.” The
new rules directly advanced the
government’s carefully articulated
interest in warnings that would
actually be noticed.
Finally, the judges’ contrasting
attitudes toward international experience and the World Health
Organization (WHO) Framework
Convention on Tobacco Control
played a pivotal role. The tobacco
companies challenged the scope
of the advertising-space rules, arguing that they were “more extensive than is necessary.” Both
courts discussed a recent Seventh
Circuit case, Entertainment Software
v. Blagojevich, that reviewed a state
law requiring a 4-square-inch “18”
sticker on any video game that
was deemed to be “sexually ex-
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plicit.” The Seventh Circuit overturned the law because the need
for such a large sticker was unsupported by evidence. It then
mused about public health labeling run amok, saying it “certainly . . . would not condone a
health department’s requirement
that half of the space on a restaurant menu be consumed by
the raw shellfish warning.” The
Reynolds Tobacco court found this
analogy persuasive and therefore
blocked the space-allocation rules.
By contrast, the court deciding
Commonwealth Brands looked to the
WHO Framework Convention,
noting that “Unlike Entertainment
Software, where the state failed to
give any reason for why a smaller
warning would be inappropriate,
Congress has provided reasons
for the particular features of the
warning requirement here. Most
obviously, it relied on the international consensus reflected in
the Framework Convention on
Tobacco Control, which calls for
warnings that ‘shall be rotating,’
‘shall be large, clear, visible and
legible,’ ‘should be 50% or more
of the principal display areas
but shall be no less than 30% of
the principal display
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areas,’ and ‘may be in the form
of or include pictures or pictograms.’”
The Framework Convention is
legally binding in 174 countries.
The United States signed the convention, but President George W.
Bush did not send it to the Senate for ratification. Nevertheless,
Congress passed and Obama
signed the Tobacco Control Act,
which largely follows the convention’s proposed space-allocation
rules. In Commonwealth Brands,
McKinley highlighted this connection to reach his conclusion that
these rules were “necessary.” By
contrast, Leon was openly skeptical of Canadian, English, and
Australian experiences with tobacco control and failed to mention the Framework Convention
at all, despite having read the
Commonwealth Brands opinion. Applying the strict-scrutiny test, he
found the space-allocation rules
unconstitutional.
These cases will be litigated
over the next few years, as they
make their way toward the Supreme Court. Already, however,

Emphasis should also be placed
on regulations such as bans on
smoking in public places, increased taxes to discourage consumption, raising the legal age
for tobacco use, smoking-cessation programs including health
insurance incentives, and outright
bans on tobacco use — all of
which are free from First Amendment concerns.
Disclosure forms provided by the author
are available with the full text of this article at NEJM.org.
From Boston University School of Law, Boston.
This article (10.1056/NEJMp1113011) was
published on December 7, 2011, at NEJM.org.

they provide more data points in
a disturbing trend: powerful corporations are increasingly using an
expanding definition of the First
Amendment to challenge public
health regulations.5 For public
health advocates, one lesson is
that the purpose and mechanism
for new regulations must be carefully articulated and documented,
especially if any conceivable First
Amendment issue can be raised.
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Med 2011;365(7):e13. (Available at NEJM.org.)
Copyright © 2011 Massachusetts Medical Society.

The Emperor of All Maladies — The Beginning of the Beginning
Robert Schwartz, M.D.

R

ichard Feynman, the eminent
physicist, once said that
“great ideas . . . do not last unless they are passed purposely
and clearly from generation to
generation.” In 1979, Horace Freeland Judson, in his magnificent
The Eighth Day of Creation, passed
to his generation the great ideas
of molecular biology. Now, Siddhartha Mukherjee gives his generation an account of the great
ideas of oncology in his Pulitzer
Prize–winning book The Emperor

of All Maladies: A Biography of Cancer
(New York: Scribner, 2010). Muk
herjee’s book unfolds the twists
and turns, successes and failures,
and hopes and despairs that led
to our understanding of cancer’s
biology and its treatment, up to
the point of the development of
imatinib. It emphasizes oncology’s
development during the century
between William Halsted’s radical mastectomy and Brian Druker’s imatinib. Mukherjee elucidates
the extraordinarily complex story
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of the great surge in oncology
that began in 1965.
A high point of this surge occurred in the late 1990s, when
Druker and Nicholas Lydon developed a new kind of drug for
treating chronic myelogenous leukemia (CML). The novelty of this
compound, imatinib (Gleevec), a
derivative of 2-phenylaminopyridine, is its ability to interfere
specifically with the out-of-control tyrosine kinase that causes
CML. Most anticancer drugs of
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